Ikonisys

📍 Parigi, France🗓 Founded 1999👥 42 employees💰 Last funded Jan 2017
Biotechnology Research🌐 ikonisys.com
Website LinkedIn
Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease. Through its breakthrough fluorescence microscopy platform, Ikonisys continues to develop a stream of oncology tests for a variety of cancers. At the center of the platform is the Ikoniscope20®, a robotic, high-throughput, microscopy system that provides a true “walk away” automated solution. In addition to providing high quality cell images, the platform analyzes the cells of interest, offering an interpretation of the analysis, to facilitate the quick, accurate reporting of the test result. In addition to automating traditional FISH-based tests, the rare cell detection and analysis capabilities of the platform, that facilitates the examination of large complex samples for the clinically relevant cells, make it particularly suitable for circulating tumor cell-based testing.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1999
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Italy
1
Frequently asked questions
Who invested in Ikonisys?
Ikonisys has 1 investors on record on gritt.io.
When did Ikonisys last raise funding?
The most recent investment in Ikonisys recorded on gritt.io was in January 2017.
When was Ikonisys founded?
Ikonisys was founded in 1999.
What industry is Ikonisys in?
Ikonisys operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Ikonisys based?
Ikonisys is headquartered in Parigi, France.